Overview
- The FDA’s Pharmacy Compounding Advisory Committee began meeting Thursday to vote on adding BPC‑157, TB‑500, KPV/MOT‑s variants, Semax, Epitalon and Emideltide to the agency’s 503A Bulks List for pharmacy compounding.
- Career FDA scientists have recommended against loosening restrictions because the seven peptides lack robust human clinical trials and raise safety concerns that include heart toxicity, infection, pancreatitis, immune reactions, altered insulin sensitivity, melanoma and death.
- Health and Human Services Secretary Robert F. Kennedy Jr. and industry advocates have pushed for expanded compounding to move the market into regulated pharmacies and reduce gray‑market risks, and thousands of public comments and rallies have pressed the panel to act.
- The advisory votes are nonbinding so the FDA can accept or reject the panel’s advice and any formal change would likely require further rulemaking or enforcement guidance that could take months or years to complete.
- If the panel recommends wider compounding, telehealth firms and compounding pharmacies could expand access but patients would still face uncertainty over dosing, long‑term harms, and quality control because these peptides have not undergone standard FDA approval.